Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely

Grupper, Ayelet; Katchman, Helena

doi:10.1111/ajt.16710

Cited by 37 publications

(37 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These two factors allow to some extent the reconstitution of immunological capacity. Our findings are in close agreement with two recent publications that demonstrated an impaired humoral and cellular immunity in KTR after vaccination, which correlated with the type and number of immunosuppressive agents [8,13]. Antimetabolites MMF/MPA seem to have a particularly unfavorable influence in this regard, which was also shown in a preliminary study by Boyarski [15].…”

Section: Discussionsupporting

confidence: 92%

“…Significantly stronger immunization was noticed in patients receiving the mRNA-1273 vaccine as compared to BNT162b2. As in other studies, age was found to be an important factor in the humoral response, so the young people have an increased capacity to mount a humoral immune response compared to the older population [5,8,13]. We discuss below these results in relation to data from the literature.…”

Section: Discussionsupporting

confidence: 51%

“…The results of our previous studies also showed a significant humoral post-vaccination response in the vast majority of dialyzed patients [5,6]. In contrast, kidney transplant recipients (KTR) demonstrated a markedly impaired seroconversion rate of 40-60% after two doses of mRNA vaccines [7][8][9]. Liver, heart, and lung transplant recipients exhibited a reduced response to mRNA-based vaccines as well [10][11][12].…”

Section: Introductionmentioning

confidence: 73%

See 2 more Smart Citations

Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project

et al. 2021

View full text Add to dashboard Cite

Background: The efficacy of SARS-CoV-2 vaccination among kidney transplant recipients (KTR) is low. The main goal of this study was to analyze factors that may influence the humoral response to vaccination. Methods: We analyzed the titer magnitude of IgG antibodies directed against spike (S)-SARS-CoV-2 antigen after the second dose of the mRNA vaccine in 142 infection naïve KTR (83 men, i.e., 58.4%) with a median age (IQR) of 54 (41–63), and 36 respective controls without chronic kidney disease. mRNA-1273 or BNT162b2 were applied in 26% and 74% of KTR, respectively. Results: S-specific immune response (seroconversion) was seen in 73 (51.41%) of KTR, and in all controls 36 (100%). Independent predictors of no response were elder age, shorter transplantation vintage, and a more than two-drug immunosuppressive protocol. In subgroup analyses, the seroconversion rate was highest among KTR without MMF/MPS treatment (70%), treated with no more than two immunosuppressants (69.2%), treated without corticosteroid (66.7%), younger patients aged <54 years (63.2%), and those vaccinated with the mRNA-1273 vaccine (62.16%). The independent predictors of higher S-antibody titer among responders were younger age, treatment with no more than two immunosuppressants, and the mRNA-1273 vaccination. Conclusions: Our study confirmed a low rate of seroconversion after vaccination with the mRNA vaccine in KTR. The major modifiable determinants of humoral response were the composition of the immunosuppressive protocol, as well as the type of vaccine. The latter could be taken into consideration when initial vaccination as well as booster vaccination is considered in KTR.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 51%

Section: Introductionmentioning

confidence: 73%

See 1 more Smart Citation

Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Compared with previously published data on the seropositivity rate after vaccination of other immunosuppressed populations, such as patients who received heart or renal transplantation, the seropositivity rate of patients with cancer in our study was higher (18–37.5% vs 84%, respectively) [ [15] , 16 , 17 , 18 ].…”

Section: Discussioncontrasting

confidence: 86%

“…[ 14 ]. Data regarding safety and efficacy of mRNA COVID-19 vaccines in patients who were immune-compromised [ [15] , 16 , 17 , 18 ] and oncology patients [ [19] , 20 , 21 , [22] , 23 ] are now beginning to emerge.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study

Shmueli

Itay

Margalit

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

Aim Patients with cancer are at an increased risk for severe coronavirus disease of 2019, thus data on the safety and efficacy of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines are essential. We conducted this prospective study of patients with cancer vaccinated with BNT162b2 and monitored for antibody response and safety. The aim was to evaluate the rate of seropositivity and define predictors for non-reactive immune response. Furthermore, we evaluated the frequency and the severity of adverse events. Methods The study included patients with solid tumours undergoing anticancer treatment and immunocompetent health-care workers serving as controls. Serum titres of the receptor-binding domain (RBD) immunoglobulin G (IgG) and neutralising antibodies were measured 2–4 weeks after each vaccine dose. Results The analysis included 129 patients, of which 70.5% patients were metastatic. Patients were treated with chemotherapy (55%), immunotherapy (34.1%), biological agents (24.8%), hormonal treatment (8.5%) and radiotherapy (4.6%), that were given either alone or in combinations. The seropositivity rate among patients with cancer and controls was 32.4% versus 59.8% (p < 0.0001) after the first dose and 84.1% versus 98.9% (p < 0.0001) after the second dose, respectively. Median RBD-IgG titre was lower among patients than controls (p < 0.0001). Patients who were seronegative after the second dose had significantly more comorbidities than that with patients with seropositivity (77.8% vs 41.1%, respectively, p = 0.0042). Conclusion Adequate antibody response after BNT162b2 vaccination was achieved after two doses but not after one dose, in patients with cancer vaccinated during anticancer therapy.

show abstract

Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients

et al. 2023

View full text Add to dashboard Cite

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely

Cited by 37 publications

References 4 publications

Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project

Predictors of Humoral Response to mRNA COVID19 Vaccines in Kidney Transplant Recipients: A Longitudinal Study—The COViNEPH Project

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study

Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients

Contact Info

Product

Resources

About